Feb. 4 at 3:10 AM
$VTVT Newsoara is a privately help company in China. VTVT just gave them th worldwide license to develop and commercialize PDE4 inhibitor, HPP737 which is currently nearing the end of its phase 3 clinical trial. Clinical data suggests HPP737 may not have the side effects common to other PDE4 inhibitors in development . VTVT got an upfront payment of
$20 million, the amended license with Newsoara includes future development milestones of up to approximately
$50 million, future sales milestones of up to
$65 million, and tiered royalties based on sales.
